Grand Pharmaceutical's (HKG:0512) phase 2 clinical trial of its STC3141 drug for sepsis in China achieved clinical endpoints, according to a Tuesday filing with the Hong Kong bourse.
The results confirmed the effectiveness and safety of STC3141 in the treatment of sepsis, showing the drug achieved a lower sequential organ failure assessment score compared with the baseline.
The first treatment program centered on rebuilding immune homeostasis worldwide, the filing said.
The trial, conducted by Grand Pharma's Australian subsidiary Grand Medical, enrolled 180 patients, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。